Kaplan Fox Initiates Probe Into Fulcrum Therapeutics Over Securities Issues After Pociredir Program Halt

Discontinuation of Pociredir Program and FDA Safety Concerns

On June 1, 2026, after market hours, Fulcrum Therapeutics announced it would discontinue the pociredir program, aimed at treating sickle cell disease (SCD). The company cited FDA concerns about the drug candidate’s benefit-risk profile in a press release. Meeting minutes from recent end-of-phase discussions with the FDA revealed intensified regulatory apprehensions regarding the program.

The FDA’s concerns centered on a high incidence of secondary hematologic malignancies observed with Tazverik4 (tazemetostat), another PRC2 inhibitor withdrawn globally in March 2026. After Fulcrum submitted additional data, the FDA concluded that all pharmacological agents targeting the PRC2 complex pose similar malignancy risks regardless of the specific subunit targeted. This determination removed any feasible regulatory pathway for further clinical development of pociredir.

Sharp Stock Price Drop Following Announcement

The market reacted swiftly and significantly to Fulcrum Therapeutics’ disclosure. On June 2, 2026, the trading day after the after-hours announcement, the stock price fell dramatically from $6.42 to $3.14 per share, a loss of $3.28 per share, equating to a 51.09% decrease in value within one session.

This steep single-day decline resulted in a substantial loss of market capitalization for shareholders and highlighted investor concerns over the discontinuation of a key pipeline asset. The after-market timing of the announcement limited investors’ ability to respond during regular trading hours before the stock price dropped.

Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics

Kaplan Fox & Kilsheimer LLP has commenced an investigation into possible securities law violations by Fulcrum Therapeutics. The firm aims to determine whether the company or its executives failed to comply with securities regulations related to the pociredir discontinuation or associated disclosures, including potential delays in revealing material information to investors.

The law firm is investigating on behalf of investors who suffered losses due to the stock price decline and is seeking information from Fulcrum Therapeutics shareholders who may have been affected or possess relevant details. Investors are urged to contact the firm to discuss potential claims or provide information.

Fulcrum Therapeutics’ Focus and Pipeline Overview

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecules targeting rare hematological disorders. Its therapeutic strategy focuses on specific molecular pathways involved in blood diseases. Prior to the discontinuation, the pociredir program was a significant part of its clinical pipeline addressing sickle cell disease, a serious rare blood disorder affecting many patients.

The termination of the pociredir program marks a major setback for the company’s development plans. Sickle cell disease is a priority area for the FDA and biopharma industry in seeking new treatments. This loss raises concerns among investors about Fulcrum’s remaining pipeline and strategic direction.

FDA Regulatory Actions on PRC2 Inhibitors

The FDA’s conclusion that all PRC2-targeting drugs carry similar malignancy risks is a pivotal regulatory development in epigenetic therapy. The global withdrawal of Tazverik4 (tazemetostat) in March 2026 after secondary hematologic malignancies were reported triggered this reassessment.

Tazemetostat, developed by a competing biopharmaceutical company, was approved for specific indications. The unexpected malignancy rates led the FDA to evaluate whether the risk was compound-specific or a class effect. The FDA’s ruling that the risk applies across all PRC2 inhibitors targeting different subunits effectively halted the regulatory pathway for pociredir and potentially other PRC2 inhibitor programs.

Kaplan Fox’s Expertise in Securities Litigation

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm specializing in complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has over five decades of experience prosecuting securities, antitrust, and consumer protection cases across federal and state courts nationwide. It has recovered more than $10 billion for clients and class members.

The firm has earned accolades from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Kaplan Fox has led or co-led major securities litigation cases, including a $2.425 billion recovery for Bank of America shareholders—the largest ever under Section 14(a) of the Securities Exchange Act—an $800 million recovery for Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch. The firm represents public pension funds, institutional investors, businesses, and individuals in high-profile litigation.

Information for Affected Fulcrum Therapeutics Investors

Investors in Fulcrum Therapeutics who suffered losses following the stock price decline are invited to contact Kaplan Fox & Kilsheimer LLP to explore potential claims. They may share information about their investments and transaction timing. The firm also seeks information from anyone with knowledge relevant to the investigation.

Kaplan Fox emphasizes that contacting the firm does not establish an attorney-client relationship nor obligate retention. Potential claimants should understand that litigation outcomes are uncertain and recovery is not guaranteed.

Announcement Timing and Investigation Focus

Fulcrum Therapeutics announced the pociredir discontinuation after market close on June 1, 2026, a key detail in the investigation. This timing delayed market reaction until the next trading day, limiting shareholders’ ability to respond promptly.

The investigation will likely assess whether material facts about the pociredir program, FDA communications, or malignancy concerns should have been disclosed earlier. Securities laws mandate timely disclosure of material information to ensure fair and equal investor access.

Wider Impact on Biopharmaceutical Development

The FDA’s ruling on PRC2 inhibitors has broader implications beyond Fulcrum’s pociredir program. It restricts development of the entire PRC2 inhibitor class for indications where malignancy risk is prohibitive. Other companies with PRC2 programs may face similar regulatory hurdles and program terminations.

This situation highlights for biopharmaceutical investors the critical importance of safety monitoring and regulatory risks in drug development. A single adverse safety signal in a related compound can significantly impact multiple programs within the same therapeutic class when regulators determine the risk is class-wide rather than compound-specific.